Drug Profile
Research programme: cardio-protective therapeutics - CapellaBio/Stem cell Theranostics
Alternative Names: chemoprotectants - CapellaBio/Stem Cell TheranosticsLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator CapellaBio; Stem Cell Theranostics
- Class Cardiotonics
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute heart failure
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Acute-heart-failure(Prevention) in USA
- 16 Dec 2015 Stem Cell Theranostics and CapellaBio agree to co-develop therapeutics in USA for Acute heart failure (Prevention)
- 16 Dec 2015 Early research in Acute heart failure (Prevention) in USA (unspecified route)